Search

Your search keyword '"Bayer AG -- Product development"' showing total 611 results
Start Over Descriptor "Bayer AG -- Product development"
611 results on '"Bayer AG -- Product development"'

1. Phase III ARANOTE trial of darolutamide plus ADT significantly reduced the risk of radiological progression or death compared to placebo plus ADT in patients with mHSPC

Subjects
Bayer AG -- Product development, Prostate cancer -- Care and treatment -- Complications and side effects, Metastasis -- Care and treatment -- Complications and side effects, Clinical trials -- Comparative analysis, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries
Abstract

Results from the phase III ARANOTE trial have shown that darolutamide plus androgen deprivation therapy (ADT) significantly reduced the risk of radiological progression or death by 46% compared to placebo [...]

Published
2024

2. Bayer presents detailed results from OASIS 3 phase III study of elinzanetant to treat VMS associated with menopause at 2024 TMS meeting

Subjects
Bayer AG -- Product development, Patient compliance, Menopause, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries
Abstract

Bayer will present detailed results from the phase III study OASIS 3, providing supporting efficacy data and sustained safety data over 52 weeks for the investigational compound elinzanetant, adding to [...]

Published
2024

3. Bayer to unveil new data from its phase III OASIS 3 long-term study of elinzanetant to treat vasomotor symptoms associated with menopause

Subjects
Bayer AG -- Product development, Patient compliance, Menopause -- Care and treatment, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries
Abstract

Bayer will present detailed results from the phase III long-term study OASIS 3, evaluating the efficacy and long-term safety of the investigational compound elinzanetant versus placebo, at the upcoming annual [...]

Published
2024

4. Bayer initiates patient enrolment in phase III SOHO-02 trial of BAY 2927088 in non-small cell lung cancer

Subjects
Bayer AG -- Product development, Medical research, Medicine, Experimental, Lung cancer, Small cell -- Care and treatment, Pemetrexed -- Product development, Lung cancer, Non-small cell -- Care and treatment, Clinical trials, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries
Abstract

Bayer announced that the first patient has been enrolled in the global phase III SOHO-02 trial, an open-label, randomized, multicenter clinical trial, assessing the efficacy and safety of investigational agent [...]

Published
2024

5. Findings from Tufts University Has Provided New Data on Clinical and Translational Science (Assessing the Net Financial Benefits of Employing Digital Endpoints In Clinical Trials)

Subjects
Bayer AG -- Product development, Medical research, Medicine, Experimental, Clinical trials -- Research, Physical fitness -- Research, Pharmaceutical industry -- Product development, Health, Tufts University
Abstract

2024 AUG 31 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Science - Clinical and Translational Science. According [...]

Published
2024

6. Bayer is advancing in studies on heart failure management showcasing late-breaking heart failure data from phase III study FINEARTS-HF with finerenone

Subjects
Bayer AG -- Product development, Apixaban -- Product development, Heart, Cardiac patients, Type 2 diabetes, Pharmaceutical industry -- Product development, Heart failure, Pharmaceuticals and cosmetics industries, Kerendia (Medication) -- Product development
Abstract

Bayer will present late-breaking Phase III data on finerenone (Kerendia) in patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of greater than or equal to 40%, [...]

Published
2024

7. Bayer begins phase II study of soluble guanylate cyclase activator, BAY3283142 in patients with chronic kidney disease

Subjects
Bayer AG -- Product development, Medical research, Medicine, Experimental, Chronic kidney failure -- Care and treatment, Clinical trials, Cardiovascular diseases -- Care and treatment, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries
Abstract

Bayer announced the start of the ALPINE-1 study, a phase II clinical trial with BAY3283142, an investigational soluble guanylate cyclase (sGC) activator, in patients with chronic kidney disease (CKD). The [...]

Published
2024

8. Bayer initiates Phase II study of sGC activator in chronic kidney disease

Subjects
Bayer AG -- Product development, Medical research, Medicine, Experimental, Chronic kidney failure -- Care and treatment, Clinical trials, Cardiovascular diseases -- Care and treatment, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

Bayer announced the start of ALPINE-1 study, a Phase II clinical trial with BAY3283142, an investigational soluble guanylate cyclase, or sGC, activator, in patients with chronic kidney disease. The results [...]

Published
2024

9. Bayer submits NDA to US FDA for elinzanetant to treat moderate to severe VMS associated with menopause

Subjects
United States. Food and Drug Administration, Bayer AG -- Product development, Women -- Health aspects, Patient compliance, Menopause -- Care and treatment, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries
Abstract

Bayer announced that a New Drug Application (NDA) for the investigational compound elinzanetant has been submitted to the US Food and Drug Administration (FDA) for the treatment of moderate to [...]

Published
2024

10. Growing number of lifesciences GCCs underscores India's importance in R&D and clinical trials

Subjects
Bayer AG -- Product development, AstraZeneca PLC -- Product development, Command and control systems -- Product development -- Statistics, Clinical trials -- Statistics, Pharmaceutical industry -- Product development -- Statistics, Food and beverage industries
Abstract

Byline: Nandita Vijayasimha, Bengaluru India's is now a key hub for lifesciences Global Capability Centers (GCCs). This according to multinational majors like Amgen, GSK, Eli Lily, Bayer, Mylan, AstraZeneca among [...]

Published
2024

11. Bayer initiates phase I study with novel targeted radionuclide therapy 225Ac-PSMA-Trillium in advanced metastatic prostate cancer

Subjects
Bayer AG -- Product development, Prostate cancer -- Health aspects, Metastasis -- Health aspects, Cancer -- Care and treatment, Clinical trials -- Health aspects, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries
Abstract

Bayer announced initiation of dosing in a phase I first-in-human clinical study with 225Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy. The investigational candidate, labelled with actinium-225 and comprising a [...]

Published
2024

12. Bayer to present results from phase III OASIS 1 and 2 of elinzanetant to treat vasomotor symptoms associated with menopause at ACOG meeting

Subjects
Bayer AG -- Product development, Patient compliance -- Research, Menopause -- Research, Health care industry -- Product development, Pharmaceutical industry -- Product development, Health care industry, Pharmaceuticals and cosmetics industries, American College of Obstetricians and Gynecologists
Abstract

Bayer will present detailed results from the pivotal phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo, at the upcoming [...]

Published
2024

13. Bayer to present data from Kerendia trial program at Heart Failure 2024 Congress

Subjects
Bayer AG -- Product development, Chronic kidney failure, Type 2 diabetes, Pharmaceutical industry -- Product development, Heart failure, Business, News, opinion and commentary, Kerendia (Medication) -- Product development
Abstract

Bayer will present Kerendia data from its comprehensive clinical trial program in patients with chronic kidney disease and type 2 diabetes in addition to data from FINEARTS-HF, the ongoing randomized, [...]

Published
2024

14. Bayer to present new long-term results and subgroup analyses from pivotal clinical trial of Eylea 8 mg in nAMD & DME at ARVO meeting

Subjects
Bayer AG -- Product development, Macular degeneration, Ophthalmology, Laser industry -- Product development, Clinical trials, Pharmaceuticals and cosmetics industries, Eylea (Medication) -- Product development, Eylea HD (Medication) -- Product development
Abstract

Bayer announced that new long-term results and subgroup analyses from the pivotal clinical trial programme of aflibercept 8 mg (Eylea 8 mg) in neovascular (wet) age-related macular degeneration (nAMD) and [...]

Published
2024

15. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough

Author

McGarvey, Lorcan, Smith, Jaclyn A., Morice, Alyn, Birring, Surinder S., Chung, Kian Fan, Dicpinigaitis, Peter V., and Niimi, Akio

Subjects
Merck & Company Inc. -- Product development, Shionogi & Company Ltd. -- Product development, Bayer AG -- Product development, Medical research, Medicine, Experimental, Patient compliance -- Research, Clinical trials -- Research, Pharmaceutical industry -- Product development, Health, Cleveland Clinic
Abstract

Introduction To determine the optimal dose of sivopixant, a highly selective P2X3 receptor antagonist, for refractory or unexplained chronic cough (RCC/UCC). Methods In this phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial, patients received sivopixant 50, 150, or 300 mg or placebo once daily for 4 weeks. The primary endpoint was a change from baseline in 24-h cough frequency (coughs/h) with sivopixant vs placebo. Results Overall, 390/406 randomized patients completed the study. Placebo-adjusted changes in hourly cough count over 24 h were 13.17% (P = 0.3532), - 1.77% (P = 0.8935), and - 12.47% (P = 0.3241) and in cough severity (visual analog scale) were 1.75 mm (P = 0.5854), - 1.21 mm (P = 0.7056), and - 6.55 mm (P = 0.0433) with sivopixant 50, 150, and 300 mg, respectively. Placebo-adjusted changes from baseline in Leicester Cough Questionnaire total scores were - 0.37 (P = 0.4207), - 0.07 (P = 0.8806), and 0.69 (P = 0.1473) with sivopixant 50, 150, and 300 mg, respectively. Additionally, 61.3%, 78.3%, 86.8%, and 71.4% of patients receiving sivopixant 50, 150, and 300 mg and placebo, respectively, reported any improvements in Patient Global Impression of Change. The incidence of treatment-emergent adverse events (TEAEs) was 25.7%, 32.0%, 49.0%, and 20.6% in sivopixant 50, 150, and 300 mg and placebo groups, respectively; all TEAEs in the sivopixant group were mild-to-moderate. Conclusion Sivopixant did not demonstrate a statistically significant difference vs placebo in change from baseline in 24-h cough frequency. The dose of 300 mg has potential for RCC/UCC, showing the greatest improvements in cough frequency and patient-reported outcomes and dose-related mild to moderate reversible taste disturbance, although further trials are needed. Clinical Trial Registration ClinicalTrials.gov identifier NCT04110054; registered September 26, 2019., Author(s): Lorcan McGarvey [sup.1], Jaclyn A. Smith [sup.2], Alyn Morice [sup.3], Surinder S. Birring [sup.4], Kian Fan Chung [sup.5], Peter V. Dicpinigaitis [sup.6], Akio Niimi [sup.7], Michael S. Benninger [sup.8], [...]

Published
2023
Full Text
View/download PDF

16. Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF [?]40% at AHA 2024

Subjects
Bayer AG -- Product development, Heart attack -- Analysis, Chronic kidney failure -- Analysis, Heart -- Analysis, Cardiac patients -- Analysis, Type 2 diabetes -- Analysis, Pharmaceutical industry -- Product development, Heart failure -- Analysis, General interest, News, opinion and commentary, Kerendia (Medication) -- Product development
Abstract

WHIPPANY: BAYER has issued the following news release: Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDIA(r) (finerenone) in heart [...]

Published
2024

17. BAYER TO PRESENT NEW PRESPECIFIED SUBGROUP ANALYSES FROM INVESTIGATIONAL PHASE III FINEARTS-HF TRIAL IN PATIENTS WITH HEART FAILURE WITH LVEF Ae[yen]40% AT AHA 2024

Subjects
Bayer AG -- Product development, Heart attack -- Analysis, Chronic kidney failure -- Analysis, Heart -- Analysis, Cardiac patients -- Analysis, Type 2 diabetes -- Analysis, Pharmaceutical industry -- Product development, Heart failure -- Analysis, News, opinion and commentary, Kerendia (Medication) -- Product development
Abstract

WHIPPANY, N.J. -- The following information was released by the Heart Failure Society of America (HFSA): Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF [...]

Published
2024

18. Multiple Sclerosis Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Biogen, Immune Response BioPharma, Celgene, Novartis, Sanofi, Actelion, Bayer, Acorda

Subjects
United States. Food and Drug Administration -- Reports, Acorda Therapeutics Inc. -- Product development, Bayer AG -- Product development, Novartis AG -- Product development, Sanofi S.A. -- Product development, Celgene Corp. -- Product development, Biological products industry -- Product development, Medical research -- Health aspects -- Reports, Medicine, Experimental -- Health aspects -- Reports, Multiple sclerosis -- Drug therapy, B cells -- Reports -- Health aspects, Clinical trials -- Health aspects -- Reports, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-October 2, 2024-: Multiple Sclerosis Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Biogen, Immune Response BioPharma, Celgene, Novartis, Sanofi, Actelion, Bayer, Acorda (C)1994-2024 M2 [...]

Published
2024

19. Bayer announces positive results from phase III study OASIS 3 of elinzanetant for moderate to severe vasomotor symptoms

Subjects
Bayer AG -- Product development, Patient compliance, Menopause, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries
Abstract

Bayer announced positive topline results of the phase III study OASIS 3 evaluating the efficacy and long-term safety of the investigational compound elinzanetant versus placebo. In this study, elinzanetant successfully [...]

Published
2024

20. Bayer begins phase II study with first-in-class anti-alpha2 antiplasmin antibody in patients with deep vein thrombosis

Subjects
Bayer AG -- Product development, Medical research, Medicine, Experimental, Viral antibodies, Clinical trials, Antibodies, Pharmaceuticals and cosmetics industries
Abstract

Bayer announced the start of a phase II clinical trial (SIRIUS study) with BAY3018250, an investigational first-in-class anti-alpha2 antiplasmin (anti-a2ap) antibody in patients with deep vein thrombosis (DVT). The results [...]

Published
2024

21. Bayer, AskBio announce first patient randomized in GenePHIT phase II trial of AB-1002 to treat congestive heart failure

Subjects
Bayer AG -- Product development, Congestive heart failure -- Care and treatment, Clinical trials, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries
Abstract

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced that the first patient has been randomized [...]

Published
2024

22. Vividion begins patient dosing in phase I trial of oral STAT3 inhibitor, VVD-130850 to treat advanced solid and haematologic tumours

Subjects
Bayer AG -- Product development, Tumors -- Drug therapy, Clinical trials, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries
Abstract

Vividion Therapeutics, Inc. (Vividion), announced that it has initiated dosing of patients in a phase I clinical trial evaluating VVD-130850, an investigational oral STAT3 inhibitor for the treatment of advanced [...]

Published
2024

23. AskBio begins phase II GenePHIT trial of AB-1002 to treat congestive heart failure

Subjects
Bayer AG -- Product development, Congestive heart failure -- Care and treatment, Clinical trials, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries
Abstract

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, have announced the initiation of GenePHIT (Gene PHosphatase [...]

Published
2024

24. Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF =40% at AHA 2024

Subjects
Bayer AG -- Product development, Heart attack -- Complications and side effects, Societies, Chronic kidney failure -- Complications and side effects, Heart, Cardiac patients, Type 2 diabetes -- Complications and side effects, Associations, institutions, etc., Heart failure -- Complications and side effects, Health, Kerendia (Medication) -- Product development -- Complications and side effects
Abstract

2024 NOV 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity & Diabetes Week -- Bayer will present three new prespecified subgroup analyses from the pivotal Phase III [...]

Published
2024

25. ESMO 2024 Late-Breaking Data: Phase III ARANOTE Trial Shows NUBEQA(r) (darolutamide) Significantly Reduced Risk of Radiological Progression or Death in Metastatic Hormone-Sensitive Prostate Cancer

Subjects
Bayer AG -- Product development, Prostate cancer, Metastasis, Cancer -- Prevention, Hormones, Androgens, Clinical trials, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary, Nubeqa (Medication) -- Product development
Abstract

WHIPPANY: BAYER has issued the following news release: Results from the investigational pivotal Phase III ARANOTE trial demonstrated that NUBEQA(r) (darolutamide) plus androgen deprivation therapy (ADT) showed a statistically significant [...]

Published
2024

26. Interstitial Lung Disease Clinical Trials 2024: FDA Approvals, Medication, Pipeline Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight

Subjects
Bayer AG -- Product development, Bristol-Myers Squibb Co. -- Product development, Boehringer Ingelheim GmbH -- Product development, Novartis AG -- Product development, AstraZeneca PLC -- Product development, Product development, Clinical trials, Riociguat, Business research, Treprostinil -- Product development, Nintedanib, Lung diseases, Pharmaceutical industry -- Product development, Pirfenidone, Business -- Research
Abstract

M2 PRESSWIRE-September 16, 2024-: Interstitial Lung Disease Clinical Trials 2024: FDA Approvals, Medication, Pipeline Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:15092024 Interstitial Lung [...]

Published
2024

27. Data from Phase III study OASIS 3

Subjects
Bayer AG -- Product development, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

BERLIN: Bayer will present detailed results from the Phase III study OASIS 3, providing supporting efficacy data and sustained safety data over 52 weeks for the investigational compound elinzanetant, adding [...]

Published
2024

28. Data from Phase III study OASIS 3 support efficacy and long-term safety of investigational compound elinzanetant in the treatment of moderate to severe vasomotor symptoms associated with menopause

Subjects
Bayer AG -- Product development, Patient compliance, Menopause -- Care and treatment, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

* Results from the Phase III OASIS 3 study further support efficacy data and sustained safety data of elinzanetant over 52 weeks, adding to the positive results of the OASIS [...]

Published
2024

29. Data from Phase III study OASIS 3 support efficacy and long-term safety of investigational compound elinzanetant in the treatment of moderate to severe vasomotor symptoms associated with menopause

Subjects
Bayer AG -- Product development, Patient compliance, Menopause -- Drug therapy, Pharmaceutical industry -- Product development, Business, international
Abstract

Germany: Bayer AG has issued the following press release: Bayer will present detailed results from the Phase III study OASIS 3, providing supporting efficacy data and sustained safety data over [...]

Published
2024

30. BlueRock Therapeutics Reports FDA clearance of IND application for investigational iPSC-derived cell therapy OpCT-001

Subjects
United States. Food and Drug Administration, Bayer AG -- Product development, Stem cells, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

Cambridge: BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, announced the clearance of its Investigational New Drug (IND) application by [...]

Published
2024

31. Bayer to unveil new data from its Phase III OASIS 3 long-term study of elinzanetant in the treatment of vasomotor symptoms associated with menopause

Subjects
Bayer AG -- Product development, Patient compliance, Menopause -- Care and treatment, Pharmaceutical industry -- Product development, Business, international
Abstract

Germany: Bayer AG has issued the following press release: Bayer will present detailed results from the Phase III long-term study OASIS 3, evaluating the efficacy and long-term safety of the [...]

Published
2024

32. Bayer to Unveil New Data From Its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated With Menopause

Subjects
Bayer AG -- Product development, Patient compliance, Menopause -- Care and treatment, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

* Detailed results from the Phase III OASIS 3 study evaluating the efficacy and long-term safety of investigational compound elinzanetant will be presented for the first time at this year's [...]

Published
2024

33. BlueRock Therapeutics announces FDA clearance of IND application for investigational iPSC-derived cell therapy OpCT-001 for the treatment of primary photoreceptor diseases

Subjects
United States. Food and Drug Administration, Bayer AG -- Product development, Stem cells, Diseases -- Care and treatment -- Germany, Pharmaceutical industry -- Product development, Business, international
Abstract

Germany: Bayer AG has issued the following press release: BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, today announced the [...]

Published
2024

34. BlueRock Therapeutics announces FDA clearance of IND application for investigational iPSC-derived cell therapy OpCT-001 for the treatment of primary photoreceptor diseases

Subjects
United States. Food and Drug Administration, Bayer AG -- Product development, Stem cells, Diseases -- Care and treatment, Banking, finance and accounting industries, Business
Abstract

Cambridge, MA USA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, today announced the [...]

Published
2024

35. Bayer starts Phase III Trial in Non-Small Cell Lung Cancer (NSCLC)

Subjects
Bayer AG -- Product development, Medical research, Medicine, Experimental, Lung cancer, Small cell -- Care and treatment, Pemetrexed -- Product development, Clinical trials, Lung cancer, Non-small cell -- Care and treatment, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

* First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naove patients with advanced NSCLC with HER2-activating mutations * Data from the phase I/II [...]

Published
2024

36. ESC Congress 2024: Bayer to Present Phase III KERENDIA® (finerenone) Data

Subjects
Bayer AG -- Product development, Chronic kidney failure, Clinical trials, Apixaban -- Product development, Heart, Cardiac patients, Type 2 diabetes, Pharmaceutical industry -- Product development, News, opinion and commentary, Kerendia (Medication) -- Product development
Abstract

WHIPPANY, N.J--(BUSINESS WIRE)--Aug 29, 2024-- Bayer will present late-breaking Phase III data from the FINEARTS-HF trial investigating KERENDIA ® (finerenone) in patients with heart failure (HF) and LVEF ≥40% (left [...]

Published
2024

37. Bayer starts Phase III trial in non-small cell lung cancer (NSCLC)

Subjects
Bayer AG -- Product development, Medical research, Medicine, Experimental, Lung cancer, Small cell -- Care and treatment, Clinical trials, Lung cancer, Non-small cell -- Care and treatment, Pharmaceutical industry -- Product development, Business, international
Abstract

Germany: Bayer AG has issued the following press release: Bayer announced today that the first patient has been enrolled in the global Phase III SOHO-02 trial, an open-label, randomized, multicenter [...]

Published
2024

38. Bayer is advancing in studies on heart failure management showcasing late-breaking heart failure data from Phase III study FINEARTS-HF with finerenone

Subjects
Bayer AG -- Product development, Apixaban -- Product development, Heart, Cardiac patients, Pharmaceutical industry -- Product development, Heart failure, Business, international
Abstract

Germany: Bayer AG has issued the following press release: Bayer will present late-breaking Phase III data on finerenone (Kerendiatm) in patients with heart failure (HF) and a left ventricular ejection [...]

Published
2024

39. Bayer Initiates Phase II Study Of Soluble Guanylate Cyclase Activator In Patients With Chronic Kidney Disease

Subjects
Bayer AG -- Product development, Medical research, Medicine, Experimental, Chronic kidney failure -- Care and treatment, Clinical trials, Cardiovascular diseases -- Care and treatment, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

BERLIN: Bayer announced the start of the ALPINE-1 study, a Phase II clinical trial with BAY3283142, an investigational soluble guanylate cyclase activator, in patients with chronic kidney disease. The results [...]

Published
2024

41. The Journal of American Medical Association (JAMA) publishes Elinzanetant Phase III data

Subjects
Bayer AG -- Product development, Patient compliance -- Research, Menopause -- Research, Medical societies -- Research, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

* OASIS 1 and 2 studies demonstrated positive results for investigational compound elinzanetant which met all primary endpoints by significantly reducing frequency and severity of moderate to severe vasomotor symptoms [...]

Published
2024

42. Bayer Initiates Phase II Study of Soluble Guanylate Cyclase Activator (BAY3283142) in Patients With Chronic Kidney Disease

Subjects
Bayer AG -- Product development, Medical research, Medicine, Experimental, Chronic kidney failure -- Care and treatment, Clinical trials, Cardiovascular diseases -- Care and treatment, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

* Soluble guanylate cyclase (sGC) activator is being studied in patients with chronic kidney disease (CKD), with potential implications for cardiovascular disease treatment * CKD is a progressive condition affecting [...]

Published
2024

43. Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint

Subjects
Bayer AG -- Product development, Prostate cancer, Metastasis, Hormones, Androgens, Clinical trials, Pharmaceutical industry -- Product development, Business, international
Abstract

Helsinki: Orion has issued the following news release: Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets [...]

Published
2024

44. Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint

Subjects
Bayer AG -- Product development, Orion Corp. -- Product development, Industrial equipment and supplies industry -- Product development, Prostate cancer, Metastasis, Hormones, Androgens, Clinical trials, Pharmaceutical industry -- Product development, Banking, finance and accounting industries, Business
Abstract

ORION CORPORATION STOCK EXCHANGE RELEASE - INSIDE INFORMATION 17 JULY 2024 at 8.30 EEST Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men [...]

Published
2024

45. Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint

Subjects
Bayer AG -- Product development, Orion Corp. -- Product development, Industrial equipment and supplies industry -- Product development, Prostate cancer, Metastasis, Hormones, Androgens, Clinical trials, Pharmaceutical industry -- Product development, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- ORION CORPORATION STOCK EXCHANGE RELEASE - INSIDE INFORMATION 17 JULY 2024 at 8.30 EEST Inside information: Phase III ARANOTE trial of darolutamide in combination with [...]

Published
2024

46. AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson's disease

Subjects
United States. Food and Drug Administration -- Innovations, Bayer AG -- Product development, Independent regulatory commissions, Genes, Diseases -- Drug therapy -- Germany -- United Kingdom, Passports, Gene therapy, Pharmaceutical industry -- Product development, Business, international
Abstract

Germany: Bayer AG has issued the following press release: Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer [...]

Published
2024

47. AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson's disease

Subjects
United States. Food and Drug Administration -- Innovations, Bayer AG -- Product development, Medical research, Medicine, Experimental, Genetic research, Genes, Diseases -- Care and treatment -- Germany -- North Carolina -- United Kingdom, Gene therapy, Clinical trials, Pharmaceutical industry -- Product development, Banking, finance and accounting industries, Business, European Union -- Innovations
Abstract

Berlin, Germany, and Research Triangle Park, N.C., USA, July 11, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1005 (formerly known as AAV2-GDNF) is being studied for the treatment [...]

Published
2024

48. Annovis Bio Greets Four New Executives to Strengthen Leadership Team

Subjects
Bayer AG -- Product development, Pfizer Inc. -- Product development, Executives, Product development, Pharmaceutical industry -- Product development, Time to market, General interest, News, opinion and commentary
Abstract

MALVERN: Annovis Bio Inc. announces the addition of four accomplished professionals to its executive team. Currently a member of our Board of Directors, Mark White brings a wealth of global [...]

Published
2024

49. Interstitial Lung Disease Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight

Subjects
Bayer AG -- Product development, Bristol-Myers Squibb Co. -- Product development, Boehringer Ingelheim GmbH -- Product development, Novartis AG -- Product development, AstraZeneca PLC -- Product development, Business -- Research, Lung diseases, Treprostinil -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-July 9, 2024-: Interstitial Lung Disease Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:09072024 Interstitial Lung [...]

Published
2024

50. Hemophilia A Clinical Trials Assessment 2024: FDA Approvals, Pipeline, Therapies, Treatment Market and Companies by DelveInsight

Subjects
Genzyme Corp. -- Product development, Bayer AG -- Product development, Pfizer Inc. -- Product development, Novo Nordisk A/S -- Product development, Sanofi S.A. -- Product development, Business -- Research, Biological products -- Product development, Biotechnology industry -- Product development, Hemophilia -- Reports, Drug approval -- Reports, Blood coagulation factor VIII -- Reports, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-July 3, 2024-: Hemophilia A Clinical Trials Assessment 2024: FDA Approvals, Pipeline, Therapies, Treatment Market and Companies by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:03072024 Hemophilia A companies are Spark Therapeutics, [...]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results